Challenging an API With Well-Known Efficacy And Safety Into More Specific Skin & Mucosal Applications

Time: 4:15 pm - 4:35 pm

Date: 30 April 2019

30-april-2019 16:15 30-april-2019 16:35 Europe/London Challenging an API With Well-Known Efficacy And Safety Into More Specific Skin & Mucosal Applications

Titrated extracts of Centella asiatica have been approved for the first time 60 years ago as API in a drug application. Since then, Centella asiatica is well known for its regenerative properties in wound healing for topical applications and venous insufficiency in oral administrations. The biological effects of titrated extracts of Centella Asiatica are now… Read more »

Making Pharmaceuticals

Synopsis

Titrated extracts of Centella asiatica have been approved for the first time 60 years ago as API in a drug application. Since then, Centella asiatica is well known for its regenerative properties in wound healing for topical applications and venous insufficiency in oral administrations.

The biological effects of titrated extracts of Centella Asiatica are now well-characterized and can be used as a basis to further encourage the use of these extracts into more specific forms of healing. In several situations the administrations of a regenerative active would indeed be of major help in improving the living conditions of people suffering from diseases. Therapeutic indications include acne scarring, skin/mucosae aggression after a fungal treatment, diabetic ulcer…

The purpose of our work is to challenge the use of this regenerative API with proven efficacy & safety in these specific applications in order to provide a real benefit for patients.

The use of a high-purity titrated extract of Centella asiatica in these types of new applications will be supported by specific in vitro data on mucosal tolerance and development of customized formulations for these routes of administration.

Speakers

« Back